Vaginal misoprostol effective for early pregnancy failure

Article

Treatment of first-trimester pregnancy failure with vaginal misoprostol is effective, well-tolerated, and acceptable to most women, according to a randomized trial.

Treatment of first-trimester pregnancy failure with vaginal misoprostol is effective, well-tolerated, and acceptable to most women, according to a randomized trial.

Over 650 women with early pregnancy failure due to anembryonic gestation, embryonic or fetal death, or incomplete or inevitable spontaneous abortion received either 800 μg of vaginal misoprostol or vacuum aspiration. Researchers administered a second dose of misoprostol on day 3 if expulsion was incomplete and performed vacuum aspiration on day 8 if expulsion was still incomplete.

Of almost 500 women receiving misoprostol, 71% had complete expulsion by day 3 and 84% by day 8. Treatment failed in 16% of the misoprostol group and in 3% of the surgical group. Treatment failure was defined as surgical treatment for the misoprostol group and repeat aspiration for the vacuum group within 30 days of initial treatment.

Zhang J, Gilles JM, Barnhart K, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353:761-769.

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.